Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy

British Journal of Cancer

Volumn 115, Issue 2, 2016, Pages 195-202

  Yamamoto, Yoichiro ^a,b   Offord, Chetan P ^c   Kimura, Go ^b   Kuribayashi, Shigehiko ^d   Takeda, Hayato ^b   Tsuchiya, Shinichi ^b,e   Shimojo, Hisashi ^a   Kanno, Hiroyuki ^a   Bozic, Ivana ^f   Nowak, Martin A ^f   Bajzer, Željko ^g   Dingli, David ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^c MAYO CLINIC   (United States)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e Ritsuzankai Iida Hospital   (Japan)

^f HARVARD UNIVERSITY   (United States)

^g MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; RADIATION DOSE; T LYMPHOCYTE; THERAPY EFFECT; BLOOD; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; THEORETICAL MODEL;

AGED; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84978370380     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.171     Document Type: Article

References (37)

1. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. Group EEUB, Group ER (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57(3): 315-321.
2. Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C (2013) Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis. J Contemp Brachytherapy 5(4): 210-214.
3. Bostancic C, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath R, Lief J, Gutman SE (2007) Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 68(5): 1431-1437.
4. Caloglu M, Ciezki J (2009) Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology 74(6): 1183-1190.
5. Caloglu M, Ciezki JP, Reddy CA, Angermeier K, Ulchaker J, Chehade N, Altman A, Magi-Galuzzi C, Klein EA (2011) PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol 80(3): 735-741.
6. Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6(1): 15-25.
7. Chira C, Taussky D, Gruszczynski N, Meissner A, Larrivee S, Carrier JF, Donath D, Delouya G (2013) Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors. Brachytherapy 12(6): 603-607.
8. Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA (2006) PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64(2): 512-517.
9. Clark WH (1991) Tumour progression and the nature of cancer. Br J Cancer 64(4): 631-644.
10. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA (2000) Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163(4): 1085-1089.
11. Critz FA, Williams WH, Levinson AK, Benton JB, Schnell FJ, Holladay CT, Shrake PD (2003) Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol 170(5): 1864-1867.
12. Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G (2007) PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 69(2): 426-433.
13. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11): 969-974.
14. Fang Y (2011) Asymptotic equivalence between cross-validations and Akaike information criteria in mixed-effects models. Journal of Data Science 9: 15-21.
15. Forys U, Waniewski J, Zhivkov P (2006) Anti-tumor immunity and tumor anti-immunity in a mathematical model of tumor immunotherapy. Journal of Biological Systems 14(1): 13-30.
16. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6): 883-899.
17. Hinnen KA, Monninkhof EM, Battermann JJ, van Roermund JG, Frank SJ, van Vulpen M (2012) Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys 82(2): 883-888.
18. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA (2006) Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 107(7): 1496-1502.
19. Hurvich CM, Tsai CL (1989) Regression and time series model selection in small samples. Biometrika 76(2): 297-307.
20. Kirilova A, Damyanovich A, Crook J, Jezioranski J, Wallace K, Pintilie M (2011) 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA 'bounce' following 125iodine brachytherapy. Int J Radiat Oncol Biol Phys 79(2): 371-378.
21. Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56(2): 295-321.
22. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL (2002) Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 54(2): 450-456.
23. Mitchell DM, Swindell R, Elliott T, Wylie JP, Taylor CM, Logue JP (2008) Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Radiother Oncol 88(1): 102-107.
24. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61(13): 5132-5136.
25. Offord C, Bajzer Z (2006) A hybrid global optimization algorithm involving simplex and inductive search. Lecture Notes Comput Sci 2074: 680-688.
26. Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chehade N, Wilkinson DA, Reddy CA, Ciezki JP (2004) PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 63(1): 110-113.
27. Prestigiacomo AF, Stamey TA (1996) Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol 155(6): 1977-1980.
28. Reed D, Wallner K, Merrick G, Buskirk S, True L (2003) Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 62(4): 683-688.
29. Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD (2012) Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335(6069): 723-727.
30. Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35(2): 51-60.
31. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104(10): 3967-3972.
32. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15): 909-916.
33. Stepanova N (1980) Course of the immune reaction during the development of a malignant tumor. Biophysics 24: 917-923.
34. Stock RG, Stone NN, Cesaretti JA (2003) Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 56(2): 448-453.
35. Stock RG, Stone NN, Wesson MF, De Wyngaert JK (1995) A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32(1): 219-225.
36. Toledano A, Chauveinc L, Flam T, Thiounn N, Solignac S, Timbert M, Rosenwald JC, Cosset JM (2006) PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Brachytherapy 5(2): 122-126.
37. Wallner KE BJ, Dattoli MJ (1997) Prostate Brachytherapy Made Complicated Vol. 14, Smart Medicine: Seattle, WA, USA.